Najpierw wprowadzenie podatku akcyzowego na saszetki nikotynowe, potem propozycja przepisów, które zmierzają do wycofania tych produktów z rynku – przedstawiciele środowisk ...

OPKO Health, Inc. (NASDAQ:OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the ...

OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a ...

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related ...

Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by intellectual disability, developmental delays, and health issues like heart defects ...

The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and ...

OPKO appears weak into the remainder of 2024 and 2025. We expect the Q3 '24 EPS announcement on November 5, '24 to languish in negative territory at -$0.09 to $0.11 close to the same -$0.11 as Q3 '23.

Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today.

Sian Capital believes Opko has several options to unlock that value, according to a presentation it delivered to the company this week. The New York-based asset management firm owns a 3% stake in ...